Astria R&D Day: Update on STAR-0215 and its Clinical Development for the Prevention of HAE Attacks
About The Event
Please join us for Astria’s R&D Day: Update on STAR-0215 and its Clinical Development for the Prevention of HAE Attacks featuring a presentation by Marc Riedl, MD, MS (Clinical Director of the US HAEA Angioedema Center at UCSD) who will discuss the current treatment landscape and opportunity to improve patient experience in hereditary angioedema (HAE).
Following Dr. Riedl’s presentation, Astria’s management team will present information on STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of HAE.
A live question and answer session with Dr. Riedl and Astria’s management team will follow the formal presentations.